-+ 0.00%
-+ 0.00%
-+ 0.00%

ONDINE BIOMEDICAL - PRIMARY ENDPOINT AND SUCCESS CRITERIA FOR LANTERN PHASE 3 STUDY REMAIN UNCHANGED

Reuters·07/13/2026 06:00:12

Please log in to view news